Kim, S., Lee, H. J., Kim, M. S., Choi, H. J., He, J., Wu, Q., . . . Fidler, I. J. (2015). Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin Cancer Res.
Stile di citazione ChicagoKim, Sun-Jin, et al. "Macitentan, a Dual Endothelin Receptor Antagonist, in Combination With Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice." Clin Cancer Res 2015.
Citazione MLAKim, Sun-Jin, et al. "Macitentan, a Dual Endothelin Receptor Antagonist, in Combination With Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice." Clin Cancer Res 2015.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.